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Abstract Agonist exposure can cause internalisation of G-
protein coupled receptors (GPCRs), which may be a part of
desensitisation but also of cellular signaling. Previous methods
to study internalisation have been tedious or only poorly
quantitative. Therefore, we have developed and validated a
quantitative method using a sphingosine-1-phosphate (S1P)
receptor as a model. Because of a lack of suitable binding
studies, it has been difficult to study S1P receptor internal-
isation. Using a N-terminal HisG-tag, S1P1 receptors on the
cell membrane can be visualised via immunocytochemistry
with a specific anti-HisG antibody. S1P-induced internal-
isation was concentration dependent and was quantified using
a microplate reader, detecting either absorbance, a fluorescent
or luminescent signal, depending on the antibodies used.
Among those, the fluorescence detection method was the
most convenient to use. The relative ease of this method
makes it suitable to measure a large number of data points,





When chronically exposed to an agonist, G-protein coupled
receptors (GPCRs) can undergo desensitisation, i.e. the
response to a given level of agonist exposure declines, and/
or more agonist is required to maintain the same response.
Various mechanisms can be involved in desensitisation,
some of which directly affect receptor responsiveness. One
of these mechanisms involves phosphorylation of activated
receptors by GPCR kinases (GRKs). This enables binding of
arrestins to the receptor, leading to uncoupling from the G-
protein and hence impaired signaling. Another, not neces-
sarily mutually exclusive mechanism of desensitisation is
internalisation of the receptor, which can be either homolo-
gous (because of activation of the receptor) or heterologous
(because of activation of other receptors or to other stimuli).
Receptor internalisation can be arrestin-dependent or inde-
pendent (Bünemann and Hosey 1999) and involves translo-
cation of the receptor from the cell membrane to the inside
of the cell. There, it is entrapped inside clathrin-coated pits
and can undergo either degradation or resensitisation.
Severalapproacheshavebeenusedinthepasttodetectand
quantifyGPCRinternalisation.Oneclassicalmethodinvolves
homogenisation of tissues or cells, differential centrifugation
to yield a plasma membrane and a microsomal fraction
followed by electrophoresis and autoradiographical analyses
of the receptor of interest in both fractions (Simpson et al.
1984). Another classical method involves labeling of all
receptors in intact cells with a lipophilic radioligand and
competition by a hydrophilic ligand, which will replace the
radioligand from sites at the cell surface but not from those
entrapped intracellularly (Staehelin et al. 1983). More
recently, genetic approaches have been used. An example
is the use of a C-terminal green fluorescent protein (GFP;
Barak et al. 1997;K a l l a le ta l .1998) to monitor receptor
localisation after ligand stimulation sometimes combined
with an algorithm to discriminate between internalised and
membrane-bound receptors (Conway et al. 1999; Fukunaga
et al. 2006;S c h l a ge ta l .2004; Hirasawa et al. 2005). This
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ArrayScanII, where the amount of internalised receptor/GFP
spots are counted and normalised against the number of
nuclei stained with Hoechst 33342. However, a GFP, or other
fluorescent tag, is relatively large (200–300 amino acids) and
can influence receptor function (McLean and Milligan
2000). Other methods use a combination of techniques, like
quantitative flow cytometry analysis of the cell surface
receptors and immunocytochemical confocal microscopy
analysis to visualise the sub-cellular localisation of the
receptor of interest (Hirasawa et al. 1998).
Detailed quantitative studies of internalisation are of
interest as this process can be the mechanism of underlying
physiological and pharmacological effects. For example,
receptor internalisation is thought to underlie the modula-
tion of immune function by sphingosine-1-phosphate (S1P;
Matloubian et al. 2004). This also appears to be the
mechanism of action of the immunosuppressive drug
FTY720 (fingolimod; Chiba et al. 2006; LaMontagne et
al. 2006), which is undergoing clinical trials for the
treatment of multiple sclerosis and previously also for renal
graft rejection (Budde et al. 2002; Kappos et al. 2006).
In our search to quantify internalisation of membrane
receptors in a fast and easy way, we have setup a method,
which uses an N-terminal HisG (6xHis+Gly)-tagged S1P1
receptor. Because the HisG-tag is N-terminal, it is extra-
cellular. Therefore, when immunocytochemistry is per-
formed without permeabilisation, only membrane-bound,
tagged receptors will be detected. This way, internalisation
is quantified as a difference in membrane-fluorescence
between unstimulated and agonist-stimulated cells.
The use of small, N-terminal tags has been described
before (Daunt et al. 1997; Vicentic et al. 2002; Wozniak and
Limbird 1996; Von Zastrow et al. 1993;M i l l e r2004). Of
these, Daunt et al. 1997 described a method where cells were
plated onto 24 well tissue culture dishes. After stimulations
with an agonist, incubations with first and second antibodies
followed. Measurements were done after adding alkaline
phosphatase substrate, resulting in a colorimetric reading. In
this paper, we now describe the validation of a similar
method by testing various antibody combinations and
detection methods to quantify internalisation of N-terminal
HisG-tagged receptors. This resulted in immunocytochemi-
cal method using a specific anti-HisG first antibody
combined with a fluorescent second antibody (AlexaFluor®
488) as our preferred choice. The signal can either be
visualised under the fluorescence microscope or measured in
a fluorescence microplate reader. The latter results in
quantitative measurement of the decrease in signal caused
by receptor internalisation, in a direct, sensitive and fast way.
Materials and methods
Materials
pcDNA3.1 containing the entire coding region of the
human S1P1 receptor was purchased from UMR cDNA
Resource Center (Rolla, MO).
Fig. 1 Western blot of CHO-FlpIn cells stably expressing the S1P1
receptor (lane 1) and HisG-S1P1 receptor (lane 2) using a mouse anti-
HisG first antibody and a goat anti-mouse HRP second antibody.
HisG-S1P1 is detected at approximately 50 kDa as indicated by the
arrow. The band at 80 kDa is nonspecific. The blot shown is from a
typical experiment out of four
Fig. 2 Fluorescence microscope
pictures of CHO-FlpIn cells sta-
bly expressing the HisG-S1P1
receptor (a) and the S1P1
receptor (b) using a mouse anti-
HisG first antibody and Alexa-
Fluor® 488 goat anti-mouse
second antibody. Images shown
are from one typical experiment
out of nine
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pcDNA3.1/His C, pOG44, CHO-FlpIn cells, Alexa Fluor®
488 goat anti-mouse (IgG), anti-HisG (mouse monoclonal
IgG2a), anti-HisG-horse radish peroxidase (HRP; mouse
monoclonal IgG2a), pcDNA5/FRT/TO, NuPAGE® System,
NuPAGE® Novex 4–12% Bis–Tris gel, MES running buffer,
NuPAGE® transfer buffer and Invitrolon™ PVDF blotting
membranes were obtained from Invitrogen (Breda, The
Netherlands). BCA™ Protein Assay Kit was obtained from
Pierce (Etten-Leur, The Netherlands). Formaldehyde solution
was obtained from Sigma (Zwijndrecht, The Netherlands).
Restriction enzymes (BamHI, XhoI, EcoRI and HindIII) were
obtained from Fermentas Life Sciences (St. Leon-Rot,
Germany). Black, clear bottom 96 well plates were obtained
from Greiner Bio One (Alphen aan den Rijn, The Nether-
lands). S1P was obtained from Avanti-Polar Lipids (via
Instruchemie B.V., Delfzijl, The Netherlands). Chamber
slides were obtained from Nunc (Amsterdam, The Nether-
lands). BM Chemiluminescence Blotting Substrate [POD]
and ABTS [2,2′-azino-bis(3-ethylbenzthiazoline-6-sulphonic
acid)] were obtained from Roche (Mannheim, Germany).
Hyperfilm ECL was obtained from Amersham Biosciences
(Diegem, Belgium). SEW2871 (5-(4-Phenyl-5-trifluorome-
thylthiophen-2-yl)-3-(3-trifluoromethylphenyl)-1,2,4-oxadia-
zole) was obtained from Calbiochem (via VWR,
Amsterdam, The Netherlands). Goat anti-mouse-HRP was
obtained from Jackson ImmunoResearch Europe (via Sanbio
B.V., Uden, The Netherlands). RIPA buffer was obtained
from Boston bio products (Worcester, UK). Halt protease
inhibitor cocktail was obtained from Pierce (via Perbio
Science Nederland B.V. Etten-Leur, The Netherlands).
Fig. 3 Fluorescence microscope
pictures of CHO-FlpIn cells sta-
bly expressing the HisG-S1P1
using a mouse anti-HisG first
antibody and AlexaFluor® 488
goat anti-mouse second anti-
body. Cells were stimulated for
30 min with 1 μM S1P or
10 μM SEW2871 at either 37°C
(left panel) or 4°C (right panel).
Images shown are from one
typical experiment out of four
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An N-terminal HisG-tag was added to the S1P1 receptor via
cloning into pcDNA3.1/HisC using BamHI and XhoI. A
second cloning step was done using HindIII and XhoIt o
clone the HisG-tagged S1P1 receptor into the expression
vector pcDNA5/FRT/TO. Transfection of plasmids into
CHO-FlpIn cells and cell culture was done as described
previously (Jongsma et al. 2006).
Western blot
Cells were washedand scraped in PBS, spun down and lysed
in RIPA buffer with protease inhibitor. Protein concentration
was determined using the BCA kit according to the
manufacturer’s protocol. Ten micrograms of protein were
loaded onto a 4–12% NuPAGE® Bis–Tris Gel. Electropho-
resis was carried out at 200 V for 40 min in NuPAGE® MES
running buffer. Protein was transferred to Invitrolon™
PVDF blotting membranes at 30 V for 1 h. The membrane
was blocked for 1 h at room temperature in 50 mg/ml non-fat
dry milk in PBS followed by overnight incubation at 4°C
with a dilution of 1:5,000 for mouse anti-HisG. After
washing with PBS-Tween (0.1%), the membrane was
incubated with a 1:20,000 dilution of goat anti-mouse-HRP
IgG at room temperature. Detection was done using BM
Chemiluminescence Blotting Substrate and Hyperfilm ECL.
Immunocytochemistry
Cells (40,000 cells/well) were plated on day 1 in 96 wells
black, clear bottom plates or eight well chamber slides. The
Fig. 4 Fluorescence microscope
pictures of CHO-FlpIn cells sta-
bly expressing the HisG-S1P1
receptor using a mouse anti-
HisG first antibody and Alexa-
Fluor® 488 goat anti-mouse
second antibody. Cells were
stimulated with S1P at the indi-
cated concentrations at 37°C for
30 min. Images shown are from
one typical experiment out of
four experiments
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After incubation overnight, cells were stimulated with the
indicated ligand in serum-free medium for 30 min at 37°C,
unless otherwise indicated. The stimulation solutions were
r e m o v e d ,a n dc e l l sw e r ef i x e db ya p p l y i n g4 %v / v
formaldehyde in PBS for 15 min at room temperature.
After washing three times with PBS, cells were incubated
with the first antibody for 1 h at room temperature. Cells
were washed again three times with PBS and, if necessary,
incubated with the second antibody for 1 h at room
temperature. Cells were washed three times with PBS
followed by measurements on a Victor2 (Wallac, Perkin
Elmer). The following antibody combinations were used:
mouse anti-HisG 1:200 with AlexaFluor® 488 goat anti-
mouse 1:500, mouse anti-HisG-HRP 1:200 and mouse anti-
HisG 1:200 with goat anti-mouse-HRP 1:500. In case an
HRP-bound antibody was used, either ABTS solution
(50 μg/ml) or BM Chemiluminescence Blotting Substrate
was added to generate an absorbance or luminescence
signal, respectively. For the absorbance signal, a 405-nm
filter was used; for the fluorescent signal, a 490-nm
excitation and a 535-nm emission filter were used.
Data analysis
Concentration response curves were analysed by fitting
sigmoidal functions to the experimental data using Prism 4
(Graphpad Software, San Diego, CA). Data are expressed
as means±SEM. Differences between groups were com-
pared using a one way analysis of variance with a Dunnett’s
correction or a Student’s t test where appropriate. P<0.05
was considered significant.
Results
Characterisation of the HisG-tagged S1P1 receptor
The presence of HisG-S1P1 receptor in stably transfected
CHO-FlpIn cells was confirmed in Western blot analysis as a
band of approximately 50 kDa (Fig. 1). The HisG-S1P1
receptor was also visualised in the cell membrane by
fluorescence microscopy using AlexaFluor® 488 goat anti-
mouse as a secondary antibody (Fig. 2). CHO-FlpIn cells
stably expressing the untagged S1P1 receptor were used as a
negative control for both detection methods (Figs. 1 and 2).
Addition of the N-terminal HisG-tag to the S1P1 receptor did
not influence signaling via this receptor as it did not
significantly alter the potency of S1P to inhibit forskolin-
stimulated cAMP accumulation (pEC50 S1P1 9.0±0.1 vs
HisG-S1P1 8.9±0.1; n=6), measured as described previously
(Jongsma et al. 2006).
Internalisation of the S1P1 receptor
A3 0 - m i ni n c u b a t i o nw i t h1μM of S1P or 10 μMo ft h e
selective S1P1 agonist SEW2871 (Sanna et al. 2004)a t3 7 ° C
decreased fluorescence (Fig. 3a, c, e). No such decrease in
fluorescence was seen when cells were incubated with either
agonist at 4°C (Fig. 3b, d, f). S1P concentration dependently
internalised the HisG-S1P1 receptor as visualised with a
fluorescence microscope (Fig. 4). Such decrease in fluores-
cence was also measured using a fluorescence microplate
reader. The fluorescent signal of cells stably expressing the
HisG-S1P1 receptor was significantly higher than for cells
stably expressing the untagged S1P1 receptor. Stimulation
with S1P (1 μM) for 30 min significantly decreased this
signal (Fig. 5).
Choice of detection method
Instead of the antibody combination mouse anti-HisG and
AlexaFluor® 488 goat anti-mouse (Fig. 6a), other combi-
nations were tested to optimise the method. The use of a
first antibody mouse anti-HisG-HRP (Fig. 6b) or a first
antibody mouse anti-HisG with a second antibody goat
anti-mouse-HRP (Fig. 6c) combined with the BM Chemi-
luminescence Blotting Substrate (POD) resulted in a
luminescence signal, which proved to be very sensitive.
However, the signal was very unstable over time, which
required the addition of the substrate by the microplate
reader. The combination of a first antibody mouse anti-
Fig. 5 Quantitative measurements of cells stably expressing HisG-
S1P1 using a mouse anti-HisG first antibody and AlexaFluor® 488
goat anti-mouse second antibody. Cells were stimulated at 37°C for
30 min at the indicated S1P concentrations. The first bar represents
cells stably expressing the S1P1 receptor without a HisG-tag. The
second bar represents cells stably expressing HisG-S1P1 incubated
without the first antibody. Statistical significance was shown between
‘vehicle’ and ‘1 μM S1P’ as well as between ‘no HisG’ and ‘vehicle’.
Data are shown as relative fluorescent units (RFU)±S.E.M. (n=3)
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with a second antibody goat anti-mouse-HRP (Fig. 6e)
combined with ABTS resulted in an absorbance signal.
This signal however, had less sensitivity compared to the
other two detection methods. The use of a first antibody
mouse anti-HisG-HRP resulted in a loss of sensitivity
compared to the combination of a first antibody mouse anti-
HisG with a second antibody goat anti-mouse-HRP. When
the combination of a first antibody mouse anti-HisG and a
second antibody AlexaFluor® 488 goat anti-mouse was
used, we measured a concentration-dependent internal-
isation of HisG-S1P1 after stimulation with either S1P or
SEW2871 (pEC50 S1P=7.4±0.1 [n=8] and pEC50
SEW2871=5.7±0.2 [n=3], respectively; Fig. 7).
Discussion
Previously reported methods to study the internalisation of
GPCRs were very labor intensive, required specific
equipment, added bulky tags and/or were poorly quanti-
tative. We have developed and validated a method that
uses stably transfected cells expressing a receptor with a
minor modification only, i.e. an N-terminal HisG-tag,
which did not influence receptor signaling. Several
Fig. 7 Effect of increasing concentrations of S1P (closed squares)o r
SEW2871 (open squares) on CHO-FlpIn cells stably expressing the
HisG-S1P1 receptor, using a mouse anti-HisG first antibody and
AlexaFluor® 488 goat anti-mouse second antibody. Stimulations were
carried out at 37°C for 30 min. The data shown represent the mean±S.
E.M. of six independent experiments performed in triplicate
Fig. 6 Quantitative measure-
ments of HisG-S1P1. Ligand
stimulations are carried out at
37°C for 30 min at the indicated
concentrations (n=3–4). Anti-
body and detection combina-
tions used are mouse anti-HisG
first antibody and AlexaFluor®
488 goat anti-mouse second an-
tibody (a); mouse anti-HisG-
HRP first antibody+POD (b);
mouse anti-HisG first antibody
and goat anti-mouse-HRP sec-
ond antibody+POD (c); mouse
anti-HisG-HRP first antibody+
ABTS (d); mouse anti-HisG
first antibody and goat anti-
mouse-HRP second antibody+
ABTS (e). Data are shown as
percentage of unstimulated±S.
E.M. An asterisk indicates sig-
nificant difference compared to
unstimulated cells; a pound sign
indicates significant difference
compared to S1P (10 nM)
stimulated cells
334 Naunyn-Schmiedeberg’s Arch Pharmacol (2007) 375:329–336antibody combinations and detection methods were tested.
The luminescent approach was very sensitive but highly
dependent on strict adherence to a specific time interval
between substrate addition and actual signal measurement.
The absorbent signal obtained using another detection
substrate resulted in a loss of sensitivity. The antibody
combination of a first HisG specific antibody and a
second AlexaFluor® 488 fluorescent antibody proved the
most convenient, resulting in a sensitive and stable signal.
Compared to previously published methods using a
similar approach (Daunt et al. 1997; Vicentic et al. 2002;
Wozniak and Limbird 1996; Von Zastrow et al. 1993), this
immunocytochemical detection of the N-terminal HisG-tag
is suitable to assess a large number of samples, e.g. to
construct detailed concentration response curves and/or
compare multiple ligands. In this regard, we showed that
S1P was approximately 50 times more potent than
SEW2871 in internalising the HisG-S1P1 receptor. This is
in good agreement with the previously reported potency
difference between the two agonists for activating the
receptor (Sanna et al. 2004). As comparable methods have
been described for adrenergic receptors as mentioned above
(Daunt et al. 1997; Vicentic et al. 2002; Wozniak and
Limbird 1996; Von Zastrow et al. 1993), it is likely that the
method we described here is also suitable for receptors
other than our model receptor, S1P1.
While our technique does not allow following internal-
isation in real time, the ability to process a large number of
samples compensates for that by studying multiple time
points. The only limitation to our method is the inability to
measure internalisation of endogenous receptors. However,
this would be possible when specific receptor antibodies are
available, which is not yet the case for our model receptor.
In conclusion, we have validated a method to quanti-
tatively measure receptor internalisation in which we use
an N-terminal HisG-tag combined with immunocytochem-
istry. It proves to be sensitive enough to discriminate
between different receptor ligands in a fast and non-
radioactive way.
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